NQO2 gene is associated with clozapine-induced agranulocytosis

Tissue Antigens

Volumn 62, Issue 6, 2003, Pages 483-491

  Ostrousky, O ^a   Meged, S ^a   Loewenthal, R ^a   Valevski, A ^a   Weizman, A ^a   Carp, H ^a   Gazit, E ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Agranulocytosis; Clozapine; NQO2; Schizophrenia

Indexed keywords

CLOZAPINE; GENE PRODUCT; MESSENGER RNA; OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE 2; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ARTICLE; CHROMOSOME; CLINICAL ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DISEASE ASSOCIATION; GENE; GENE SEQUENCE; GENETIC CODE; HUMAN; INTRON; NQO2 GENE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; REDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGRANULOCYTOSIS; CLOZAPINE; DENSITOMETRY; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); QUINONE REDUCTASES;

EID: 0345688810     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0039.2003.00133.x     Document Type: Article

References (43)

1. Abt K, Gulich A, Krupp P, Reinberg W. HLA-associations in Leponex/Clozaril (Clozapine)-induced granulocytopenia and agranulocytosis. Drug Saf 1992: 7: 10-6.
2. Baidessarini RJ & Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991: 324: 746-54.
3. Dale DC. Neutropenia and neutrophilia. In: Beutler E, Coller BS, Marshall AL, Kipps TJ, Seligsohn U, eds. Williams Hematology, 6th edn. USA: McGraw-Hill companies, Medical publishing division, 2001, 827-8.
4. Feldmen J. Clozapine and agranulocytosis. Psychiatr Serv 1996: 47: 1177-8.
5. Fitton A & Heel RC. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990: 40: 722-47.
6. Guest I, Sokoluk B, MacCrimmon J, Uetrecht J. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998: 131: 53-65.
7. Gerson SL & Meltzre H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf 1992: 7: 17-25.
8. Tschen AC, Rieder MJ, Oyewumi LK, Freeman DJ. The cytotoxicity of the clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 1999: 65: 526-32.
9. Liu ZC & Uetrecht J. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J Pharmacol Exp Ther 1995: 275: 1476-83.
10. Buttke TM & Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994: 15: 7-10.
11. Homburg C & Roos D. Apoptosis of neutrophils. Curr Opin Hematol 1996: 3: 94-9.
12. Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Liebermann JA. On the possible mechanisms and predictability of clozapine-induced agranulocytosis. Drug Saf 1992: 7: 33-44.
13. Uetrecht JP. Reactive metabolites and agranulocytosis. Eur J Haematol 1996: 57: 83-8.
14. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JS, Park BK. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997: 283: 1375-82.
15. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990: 47: 945-8.
16. Dettling M & Cascorbi I. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish Caucasian sample. Arch Gen Psychiatry 2001: 58: 3-4.
17. Valevski A, Klein T, Gazit E et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998: 25: 11-3.
18. Yunis JJ, Lieberman J, Yunis ED. Major histocompatibility complex associations with clozapine-induced agranulocytosis. Drug Saf 1992: 7: 7-9.
19. Yunis JJ, Corzo D, Salazar M, Lieberman J, Howard A, Yunis ED. HLA associations in clozapine-induced agranulocytosis. Blood 1995: 86: 1177-83.
20. Corzo D, Yunis JJ, Yunis EJ, Howard A, Lieberman JA. HSP70-2 9.0kb variant is in linkage disequilibrium with the HLA-B and DRB1* alleles associated with clozapine-induced agranulocytosis. J Clin Psychiatry 1994: 55 (Suppl. B): 149-52.
21. Corzo D, Yunis JJ, Salazar M et al. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995: 86: 3835-40.
22. Jaiswal AK. Human NAD(P)H: quinone oxidoreductase 2. Gene structure, activity, and tissue-specific expression. J Biol Chem 1994: 269: 14502-8.
23. Chen S, Wu K, Knox R. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2). Free Radic Biol Med 2000: 29: 276-84.
24. Jaiswal AK. Regulation of genes encoding NAD(P)H: quinone oxidoreductases. Free Radic Biol Med 2000: 29: 254-62.
25. Long DJ & Jaiswal AK. NRH: quinone oxidoreductase 2 (NQO2). Chem Biol Interact 2000: 129: 99-112.
26. Zimmermann K & Mannhalter JW. Technical aspects of quantitative competitive PCR. Biotechniques 1996: 21: 268-79.
27. Iida A, Sekine A, Saito S et al. Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J Hum Genet 2001: 46: 225-40.
28. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 2001: 288: 887-92.
29. 2+-and cyclic AMP-dependent gene transcription. Sci STKE 2001: 94: PE1.
30. Negrier C, Vinciguerra C, Attali O, Grenier C, Larcher ME, Dechavanne M. Illegitimate transcription: its use for studying genetic abnormalities in lymphoblastoid cells from patients with Glanzmann thrombasthenia. Br J Haematol 1998: 100: 33-9.
31. Wu K, Knox R, Sun XZ et al. Catalytic properties of NAD(P)H: quinone oxidoreductase 2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys 1997: 347: 221-8.
32. Americo J, Filho F, Vedeler CA, Myhr KM, Nyland H, Pandey J. TNF-α and -β gene polymorphisms in multiple sclerosis: A highly significant role for determinants in the first intron of the TNF-β gene. Autoimmunity 2002: 35: 377-80.
33. Majewski J & Ott J. Distribution and characterization of regulatory elements in the human genome. Genome Res 2002: 12: 1827-36.
34. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal development, and leukemia. Blood 1997: 90: 489-519.
35. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 1999: 25: 241-8.
36. Misso NL, Peacock CD, Watkins DN, Thompson PJ. Nitrite generation and antioxidant effects during neutrophil apoptosis. Free Radic Biol Med 2000: 28: 934-43.
37. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995: 272: 984-90.
38. Maggs L, Williams D, Pirmohamed M, Park B. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 1995: 275: 1463-75.
39. Williams DP, Pirmohamed M, Naisbitt DJ, Uetrecht JP, Park BK. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol Pharmacol 2000: 58: 207-16.
40. Naisbitt DJ, Williams DP, O'Nell PM et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol 1998: 11: 1586-97.
41. Powis G, See KL, Santone KS, Melder DC, Hodnett EM. Quinoneimines as substrates for quinone reductase (NAD(P)H: (quinone-acceptor) oxidoreductase) and the effect of dicumarol on their cytotoxicity. Biochem Pharmacol 1987: 36: 2473-9.
42. Tudor G, Gutierrez P, Aguilera-Gutierrez A, Sausvill EA. Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression. Biochem Pharmacol 2003: 65: 1061-75.
43. Iverson S, Zahid N, Uetrecht JP. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an vitro apoptosis assay for identifying drugs that may cause agranulocytosis. Chem Biol Interact 2002: 142: 175-99.